[
  {
    "ts": "2025-08-26T20:09:21+00:00",
    "headline": "Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win",
    "summary": "Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.",
    "url": "https://www.investors.com/news/technology/gilead-sciences-hiv-prep-yeytuo-yeztugo/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "de936fbf-ab41-3b22-a69e-18184c896a96",
      "content": {
        "id": "de936fbf-ab41-3b22-a69e-18184c896a96",
        "contentType": "STORY",
        "title": "Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win",
        "description": "",
        "summary": "Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.",
        "pubDate": "2025-08-26T20:09:21Z",
        "displayTime": "2025-08-26T20:09:21Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/de936fbf-ab41-3b22-a69e-18184c896a96/gilead-sciences-99-9-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/b8066fe61603e0a00cb19aadc939e17d",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ioTNJ3H5yU7eEGWF7SZr1A--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/b8066fe61603e0a00cb19aadc939e17d.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NupNPwOICtPRr6GsLaoduQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/b8066fe61603e0a00cb19aadc939e17d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/gilead-sciences-hiv-prep-yeytuo-yeztugo/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-26T13:40:00+00:00",
    "headline": "GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU",
    "summary": "Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.",
    "url": "https://finance.yahoo.com/news/gild-wins-approval-twice-yearly-134000254.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "90139ba1-26e3-36e5-86c2-2399fcdc3e1b",
      "content": {
        "id": "90139ba1-26e3-36e5-86c2-2399fcdc3e1b",
        "contentType": "STORY",
        "title": "GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU",
        "description": "",
        "summary": "Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.",
        "pubDate": "2025-08-26T13:40:00Z",
        "displayTime": "2025-08-26T13:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/be92d53349e9fe392d730a7a723f3358",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SboUKe_W9067T1LVniRLdQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/be92d53349e9fe392d730a7a723f3358.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uw0pEVH0XNH4aS_Qhxpglg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/be92d53349e9fe392d730a7a723f3358.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gild-wins-approval-twice-yearly-134000254.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gild-wins-approval-twice-yearly-134000254.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "CVS"
            },
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-26T11:43:33+00:00",
    "headline": "Gilead’s Yeytuo approved in EU, boosting its blockbuster potential",
    "summary": "Analysts and charities have identified Gilead’s new HIV prevention injection as key to curbing infection rates.",
    "url": "https://www.pharmaceutical-technology.com/news/gileads-yeytuo-approved-in-eu-boosting-its-blockbuster-potential/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "77d94ec0-7cef-3b4f-9bf0-82e58b76141d",
      "content": {
        "id": "77d94ec0-7cef-3b4f-9bf0-82e58b76141d",
        "contentType": "STORY",
        "title": "Gilead’s Yeytuo approved in EU, boosting its blockbuster potential",
        "description": "",
        "summary": "Analysts and charities have identified Gilead’s new HIV prevention injection as key to curbing infection rates.",
        "pubDate": "2025-08-26T11:43:33Z",
        "displayTime": "2025-08-26T11:43:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/a6039025ab5b81a6716c4f998a15eb75",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eehiItHDyveJgMoKc.a6bA--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/a6039025ab5b81a6716c4f998a15eb75.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OvLr.s_IjS14TLiZHvqyDA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/a6039025ab5b81a6716c4f998a15eb75.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/gileads-yeytuo-approved-in-eu-boosting-its-blockbuster-potential/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-yeytuo-approved-eu-boosting-114333773.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-26T08:57:51+00:00",
    "headline": "Gilead wins European approval for HIV prevention injection",
    "summary": "Investing.com -- Gilead Sciences (NASDAQ:GILD) said Tuesday it has received European Commission (EC) approval for its twice-yearly injection to prevent HIV, a key regulatory milestone following its U.S. clearance earlier this year.",
    "url": "https://finance.yahoo.com/news/gilead-wins-european-approval-hiv-085751136.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "5744d060-227b-3f6b-a560-d6e668754c6d",
      "content": {
        "id": "5744d060-227b-3f6b-a560-d6e668754c6d",
        "contentType": "STORY",
        "title": "Gilead wins European approval for HIV prevention injection",
        "description": "",
        "summary": "Investing.com -- Gilead Sciences (NASDAQ:GILD) said Tuesday it has received European Commission (EC) approval for its twice-yearly injection to prevent HIV, a key regulatory milestone following its U.S. clearance earlier this year.",
        "pubDate": "2025-08-26T08:57:51Z",
        "displayTime": "2025-08-26T08:57:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-wins-european-approval-hiv-085751136.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-wins-european-approval-hiv-085751136.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-26T07:00:00+00:00",
    "headline": "European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention",
    "summary": "FOSTER CITY, Calif., August 26, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35kg. Yeytuo is the first and only twice-yearly PrEP option to be approved for u",
    "url": "https://finance.yahoo.com/news/european-commission-authorizes-twice-yearly-070000419.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "3b0acf1b-2d29-351d-a00b-7b19c1b61dc0",
      "content": {
        "id": "3b0acf1b-2d29-351d-a00b-7b19c1b61dc0",
        "contentType": "STORY",
        "title": "European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention",
        "description": "",
        "summary": "FOSTER CITY, Calif., August 26, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35kg. Yeytuo is the first and only twice-yearly PrEP option to be approved for u",
        "pubDate": "2025-08-26T07:00:00Z",
        "displayTime": "2025-08-26T07:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/681cb6fbfac6216fa15d5a1bd952fda9",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yuRuBo5HctrUkSWdPnnMBA--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/681cb6fbfac6216fa15d5a1bd952fda9.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K3AUhzUcnDRVrqyPULylww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/681cb6fbfac6216fa15d5a1bd952fda9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/european-commission-authorizes-twice-yearly-070000419.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/european-commission-authorizes-twice-yearly-070000419.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]